Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03294694 · ClinicalTrials.gov registry record · Phase 1
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT03294694 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 33 participants.
The verdict
NCT03294694, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This clinical trial is studying the drug Ribociclib (LEE011) in combination with an immunotherapy drug called PDR001 (a therapy that uses the body's own immune system to control cancer) as a possible treatment for metastatic hormone-receptor-positive (HR+), HER2-negative breast cancer (in combination with fulvestrant) or metastatic epithelial ovarian cancer. The names of the medications involved in this study are: * Ribociclib (LEE011) * PDR001 * Fulvestrant
Interventions
- DRUG Fulvestrant
- DRUG Ribociclib
- DRUG PDR001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-11-08 |
| Est. Completion | 2020-10-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03294694
The ClinicalTrials.gov registry entry for NCT03294694 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fulvestrant is the first listed.
NCT03294694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03294694 about?
NCT03294694 is a clinical study titled "Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer". This clinical trial is studying the drug Ribociclib (LEE011) in combination with an immunotherapy drug called PDR001 (a therapy that uses the body's own immune system to control cancer) as a possible treatment for metastatic hormone-receptor-positive (HR+), HER2-negative breast cancer (in combinatio...
What is the current status of trial NCT03294694?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2017-11-08. Estimated completion is 2020-10-14.
What interventions are being tested in trial NCT03294694?
The interventions under investigation include: Fulvestrant (DRUG), Ribociclib (DRUG), PDR001 (DRUG).
Who is sponsoring clinical trial NCT03294694?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.